ATE224364T1 - Beta-sulfonamido hydroxamsäure als matrix metalloproteinase und als tace inhibitoren - Google Patents

Beta-sulfonamido hydroxamsäure als matrix metalloproteinase und als tace inhibitoren

Info

Publication number
ATE224364T1
ATE224364T1 AT97912674T AT97912674T ATE224364T1 AT E224364 T1 ATE224364 T1 AT E224364T1 AT 97912674 T AT97912674 T AT 97912674T AT 97912674 T AT97912674 T AT 97912674T AT E224364 T1 ATE224364 T1 AT E224364T1
Authority
AT
Austria
Prior art keywords
beta
hydroxamic acid
matrix metalloproteinase
tace inhibitors
sulfonamido
Prior art date
Application number
AT97912674T
Other languages
English (en)
Inventor
Jeremy Ian Levin
Arie Zask
Yansong Gu
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE224364T1 publication Critical patent/ATE224364T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT97912674T 1996-10-16 1997-10-08 Beta-sulfonamido hydroxamsäure als matrix metalloproteinase und als tace inhibitoren ATE224364T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72935996A 1996-10-16 1996-10-16
PCT/US1997/018170 WO1998016506A1 (en) 1996-10-16 1997-10-08 Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors

Publications (1)

Publication Number Publication Date
ATE224364T1 true ATE224364T1 (de) 2002-10-15

Family

ID=24930685

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97912674T ATE224364T1 (de) 1996-10-16 1997-10-08 Beta-sulfonamido hydroxamsäure als matrix metalloproteinase und als tace inhibitoren

Country Status (17)

Country Link
EP (1) EP0934259B1 (de)
JP (1) JP2001502326A (de)
KR (1) KR20000049198A (de)
CN (1) CN1105101C (de)
AR (1) AR008676A1 (de)
AT (1) ATE224364T1 (de)
AU (1) AU736134B2 (de)
BR (1) BR9712524A (de)
CA (1) CA2268895A1 (de)
DE (1) DE69715647T2 (de)
DK (1) DK0934259T3 (de)
ES (1) ES2184069T3 (de)
IL (1) IL129149A (de)
NZ (1) NZ335053A (de)
PT (1) PT934259E (de)
WO (1) WO1998016506A1 (de)
ZA (1) ZA979236B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69917124T2 (de) * 1998-04-10 2005-05-12 Pfizer Products Inc., Groton Cyclobutyl-Aryloxysulfonylamin-Hydroxamsäurederivate
CA2333554A1 (en) * 1998-06-17 1999-12-23 Chu-Baio Xue Cyclic hydroxamic acids as metalloproteinase inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
CN1178915C (zh) 1999-01-27 2004-12-08 惠氏控股有限公司 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
AU2320500A (en) * 1999-02-02 2000-08-25 Shionogi & Co., Ltd. Sulfonamide derivatives having cyclic structures
IL153045A0 (en) * 2000-05-23 2003-06-24 Osmonics Inc Modified sulfonamide polymers
MXPA04004010A (es) 2001-11-01 2004-07-23 Wyeth Corp Acidos hidroxamicos de aril sulfonamida alenicos como inhibidores de tace y metaloproteinasa de matriz.
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
WO2005092844A1 (en) * 2004-03-22 2005-10-06 Southern Research Institute Nonpeptide inhibitors of matrix metalloproteinases
FR2947268B1 (fr) * 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2947270B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US20140275108A1 (en) 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
ES2695533T3 (es) 2016-02-01 2019-01-08 Galderma Res & Dev Compuestos de bencenosulfonamida, método para su síntesis y uso de los mismos en medicina y cosméticos
AU2019352741A1 (en) 2018-10-04 2021-05-06 Assistance Publique-Hôpitaux De Paris (Aphp) EGFR inhibitors for treating keratodermas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
JPH08511509A (ja) * 1993-04-07 1996-12-03 グリコメド・インコーポレイテッド 合成マトリックスメタロプロテアーゼ阻害剤およびその用途
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids

Also Published As

Publication number Publication date
JP2001502326A (ja) 2001-02-20
CN1105101C (zh) 2003-04-09
CN1240424A (zh) 2000-01-05
ZA979236B (en) 1999-07-15
WO1998016506A1 (en) 1998-04-23
CA2268895A1 (en) 1998-04-23
ES2184069T3 (es) 2003-04-01
PT934259E (pt) 2003-01-31
DK0934259T3 (da) 2003-01-27
EP0934259B1 (de) 2002-09-18
EP0934259A1 (de) 1999-08-11
BR9712524A (pt) 1999-10-19
HK1020720A1 (en) 2000-05-19
AU4979097A (en) 1998-05-11
NZ335053A (en) 2000-10-27
DE69715647T2 (de) 2003-02-20
KR20000049198A (ko) 2000-07-25
IL129149A0 (en) 2000-02-17
DE69715647D1 (en) 2002-10-24
AR008676A1 (es) 2000-02-09
AU736134B2 (en) 2001-07-26
IL129149A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
ATE224364T1 (de) Beta-sulfonamido hydroxamsäure als matrix metalloproteinase und als tace inhibitoren
ATE257151T1 (de) Hydroxamsäure-derivate als matrix metalloproteinaseinhibitoren
DK0938471T3 (da) Fremstillingen og anvendelsen af ortho-sulfonamido-arylhydroxamsyrer som matrix-metalloproteinase- og TACE-inhibitorer
ATE219058T1 (de) Alpha-substituierte arylsulphonamidohydroxamsaüre als tnf-alpha und matrix-metalloproteinase- inhibitoren
BR9510175A (pt) Inibidores contendo ácido hidroxâmico de metaloproteases de matriz
FI972160A7 (fi) Matriisimetalloproteaasi-inhibiittorit
FI962904L (fi) Metalloproteinaasi-inhibiittoreita
FI962905A7 (fi) Metalloproteinaasi-inhibiittoreita
FI954351A7 (fi) Hydroksaamihappojohdannaiset metalloproteinaasi-inhibiittoreina
ATE226590T1 (de) Phosphinsäureamide als matrix metalloprotease inhibitoren
ZA979238B (en) The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors.
NO991922L (no) Heteroarylsuccinamider og deres anvendelse som metalloproteinaseinhibitorer
DK0977733T3 (da) Arylsulfonylaminohydroxamsyrederivater
FI972198A7 (fi) Metalloproteinaasi-inhibiittoreita
DE60008548D1 (de) Hydroxamsäurederivate als matrix-metalloproteinase-inhibitoren
GB9613547D0 (en) Matrix metalloproteinase inhibitors
DE60012303D1 (de) Alkinylische hydroxamsäureverbindungen als tace inhibitoren
HUP0100564A3 (en) Matrix metalloproteinase inhibitors and pharmaceuticals comprising them
BR9707024A (pt) Inibidores de colagenase com base em ácido hidroxâmico
ATE227288T1 (de) Acetylenische ortho-sulfonamido- und phosphinsäure-amido-bicyclische heteroarylhydroxamsäure als tace-inhibitoren
DK0929517T3 (da) Hydroxamsyrederivater
GB9708133D0 (en) Novel use of matrix metalloproteinase inhibitors
GB9702085D0 (en) Matrix metalloproteinase inhibitors
ATE228999T1 (de) Metalloproteinaseinhibitoren
FI965153A7 (fi) Metalloproteinaasi-inhibiittorit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
REN Ceased due to non-payment of the annual fee